## RMD: ResMed Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 0.1% below STRENGTH zone (4.0-10.0%); PEG 1.62 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($233.64)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 6
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors**
- Source: WebWire | 20251215T150943 | Bullish | Relevance: 100%
- AdvaMed, the Medtech Association, has announced that Michael "Mick" Farrell, Chairman and CEO of Resmed Inc., will serve as the next chair of its Board of Directors for a two-year term starting in January 2026. Farrell plans to focus on accelerating patient-first innovation, advancing digital transformation, and expanding global access to medtech. He succeeds Peter J. Arduini of GE HealthCare, who oversaw significant growth and integration for AdvaMed.

**2. ResMed (NYSE:RMD) Downgraded to "Hold" Rating by Baird R W**
- Source: MarketBeat | 20251217T135046 | Somewhat-Bearish | Relevance: 100%
- Baird R W has downgraded ResMed (NYSE:RMD) from a "strong-buy" to a "hold" rating, despite the company recently beating quarterly earnings and revenue estimates. Analyst sentiment overall remains "Moderate Buy" with an average price target of $297.00. Insider selling activity has also been noted, with directors selling shares totaling over $1 million combined.

**3. 4,600 Shares in ResMed Inc. $RMD Purchased by Sanders Morris Harris LLC**
- Source: MarketBeat | 20251217T122421 | Somewhat-Bullish | Relevance: 100%
- Sanders Morris Harris LLC has acquired a new position in ResMed Inc. (NYSE:RMD), purchasing 4,600 shares valued at approximately $1.26 million. Other institutional investors have also increased their holdings, with analysts giving ResMed a "Moderate Buy" rating and an average target price of $297.00. The company recently exceeded quarterly EPS and revenue estimates, and declared a quarterly dividend of $0.60 per share.

**4. ResMed (RMD) Downgraded by Baird, Price Target Lowered to $275 | RMD Stock News**
- Source: GuruFocus | 20251216T122853 | Bearish | Relevance: 100%
- Baird has downgraded ResMed (RMD) from an Outperform rating to Neutral, lowering its price target from $300 to $275. This contrasts with recent analyst activities that maintained or raised ratings for the company. ResMed, a leading respiratory care device company, focuses on sleep apnea treatment and digital health initiatives.

**5. Baird downgrades ResMed stock rating to Neutral on slowing growth**
- Source: Investing.com | 20251216T100828 | Somewhat-Bearish | Relevance: 100%
- Baird downgraded ResMed (NYSE:RMD) from Outperform to Neutral, lowering its price target to $275.00 due to decelerating growth over the past three quarters. The firm noted slowing performance in ResMedâ€™s U.S. masks and other category and expressed caution about increasing competition from private entities like React Health. Despite recent strong Q4 2025 earnings which exceeded forecasts, the downgrade reflects concerns about limiting multiple expansion and potential pricing concessions.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-16 | Baird | $275 | $300 | -8% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-16 | Baird | down | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 16 ($9.01M) |
| Sells | 17 ($5.01M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 3 / 6 |

**Top Holders:**
- Vanguard Group Inc: 13.1% (+1.6%)
- Blackrock Inc.: 8.4% (-1.3%)
- State Street Corpora: 4.5% (-1.0%)
- Bank Of New York Mel: 3.1% (-9.8%)
- Geode Capital Manage: 2.9% (+0.9%)

### Key Risks

1. Insider selling cluster: $5.0M in recent transactions.
2. Elevated short interest (8.2%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +1.4% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 1.62 elevated, pricing in significant growth expectations. Quality metrics strong (ROE 25%, ROA 14%, margin 27%). Balance sheet: strong liquidity (2.9x), low leverage (D/E 0.36). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (3 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $35.9B |
| Beta | 0.87 |
| 52W Range | $199.92 - $293.81 |
| Short Interest | 8.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.62 |
| Forward P/E | 20.5 |
| Current P/E | 22.6 |
| YoY Growth | 10.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.3% to 0.1% (+1.4% in 5 days), confirming momentum buildup. Below STRENGTH zone by 3.9pp (needs >4.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Below SMA200 (0.97x), long-term trend not supportive. RSI neutral at 42. OFD pattern: -MTN (Decline).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.08% (CS: 30) | Neutral |
| RSI_14 | 41.7 | Neutral |
| MACD Histogram | 0.01 | Bullish |
| vs SMA20 | 0.981x | Below |
| vs SMA50 | 0.962x | Below |
| vs SMA200 | 0.971x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $246.02
- **Stop Loss:** $233.64 (5.0% risk)
- **Target:** $258.40 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 87
- **Position Value:** $21,403.74
- **Portfolio %:** 21.40%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-05 (Est: $2.71)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.50 | $2.55 | +2.0% |
| 2025Q2 | $2.48 | $2.55 | +2.8% |
| 2025Q1 | $2.36 | $2.37 | +0.4% |
| 2024Q4 | $2.31 | $2.43 | +5.0% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*